Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)

Known as: A-dmDT390-bisFv(UCHT1) 
A bivalent recombinant fusion protein immunotoxin derived from the anti-CD3 monoclonal antibody UCHT1 with potential antineoplastic activity. Anti… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
01220082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin… (More)
  • figure 1
  • table 1
Is this relevant?
2009
2009
e19511 Background: T cell lymphomas represent 12% of lymphoma cases in the U.S. Cytotoxic chemotherapies, radiation therapies… (More)
Is this relevant?
2008
2008
The bivalent anti-human T cell immunotoxin A-dmDT390-bisFv(UCHT1) for treatment of patients with T cell malignancies is a single… (More)
  • table 2
  • table 4
  • table 5
  • figure 1
  • figure 2
Is this relevant?
2008
2008
The bivalent anti-T cell immunotoxin, A-dmDT390-bisFv(UCHT1), was developed for treatment of T-cell leukemia, autoimmune diseases… (More)
Is this relevant?